{"protocolSection":{"identificationModule":{"nctId":"NCT01152996","orgStudyIdInfo":{"id":"LuAA21004_314"},"secondaryIdInfos":[{"id":"U1111-1115-4927","type":"REGISTRY","domain":"WHO"}],"organization":{"fullName":"Takeda","class":"INDUSTRY"},"briefTitle":"Safety and Tolerability of Vortioxetine (LuAA21004) - Open Label Extension Study","officialTitle":"A Phase 3, Long-Term, Open-Label, Flexible-Dose, Extension Study Evaluating the Safety and Tolerability of Lu AA21004 (15 and 20 mg) in Subjects With Major Depressive Disorder"},"statusModule":{"statusVerifiedDate":"2014-04","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2010-09"},"primaryCompletionDateStruct":{"date":"2013-05","type":"ACTUAL"},"completionDateStruct":{"date":"2013-05","type":"ACTUAL"},"studyFirstSubmitDate":"2010-06-28","studyFirstSubmitQcDate":"2010-06-28","studyFirstPostDateStruct":{"date":"2010-06-29","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-04-29","resultsFirstSubmitQcDate":"2014-04-29","resultsFirstPostDateStruct":{"date":"2014-05-28","type":"ESTIMATED"},"dispFirstSubmitDate":"2013-10-08","dispFirstSubmitQcDate":"2013-11-21","dispFirstPostDateStruct":{"date":"2013-12-16","type":"ESTIMATED"},"lastUpdateSubmitDate":"2014-04-29","lastUpdatePostDateStruct":{"date":"2014-05-28","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Takeda","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"The purpose of this study is to determine the long-term safety and tolerability of vortioxetine, once daily (QD), in participants with major depressive disorder.","detailedDescription":"Depression has been recognized as a chronic illness that imposes a significant burden on individuals, families and society. Major depressive disorder (MDD) is among the most important causes of disability worldwide, in both developing and developed countries. Major depressive disorder is reported to be the most common mood disorder, with a lifetime prevalence of about 15% and as high as 25% in women. Major depressive disorder is characterized by the presence of 1 or more major depressive episodes that presents with depressed mood, loss of interest or pleasure, disturbed sleep or appetite, low energy, feelings of guilt or low self-worth, and poor concentration.\n\nThis is a multicenter extension study designed to allow eligible patients who have completed short-term efficacy and safety studies LuAA21004\\_315 (NCT01153009), LuAA21004\\_316 (NCT01163266) and LuAA21004\\_317 (NCT01179516) to receive the 52-week treatment with vortioxetine in this open-label extension study. Participants are expected to return to the site for approximately 13 visits.\n\nA safety follow-up call will be made 4 weeks after completion of the 52-week treatment period."},"conditionsModule":{"conditions":["Depressive Disorder, Major"],"keywords":["Depression","Melancholia","Paraphrenia","Drug Therapy"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":1075,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Vortioxetine","type":"EXPERIMENTAL","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.","interventionNames":["Drug: Vortioxetine"]}],"interventions":[{"type":"DRUG","name":"Vortioxetine","description":"Vortioxetine tablets","armGroupLabels":["Vortioxetine"],"otherNames":["LuAA21004"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%","description":"Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.","timeFrame":"Over the 52 week period"},{"measure":"Number of Participants With Serious Treatment-Emergent Adverse Events","description":"Serious treatment-emergent adverse events (serious-TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A serious-TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered serious adverse events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.","timeFrame":"Over the 52 week period"},{"measure":"Treatment-Emergent Adverse Events Leading to Study Discontinuation","description":"Treatment-emergent adverse events are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.","timeFrame":"Over the 52 week period"}],"secondaryOutcomes":[{"measure":"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","description":"The change between MADRS total score at each assessed visit and MADRS score at baseline. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.","timeFrame":"Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52"},{"measure":"Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score","description":"The change between HAM-A score at each assessed visit and HAM-A score at baseline. HAM-A is a 14 item rating scale to quantify anxiety symptomatology severity (i.e., anxious mood, tension, fear, insomnia, etc.) rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56. Higher scores indicate greater severity of symptoms.","timeFrame":"Baseline and Weeks 4, 24, and 52"},{"measure":"Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)","description":"The change between CGI-S score at each assessed visit and CGI-S score at baseline. The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: \"Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?\" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill). Higher scores indicate greater severity of illness.","timeFrame":"Baseline and Weeks 4, 24, and 52"},{"measure":"Change From Baseline in Sheehan Disability Scale (SDS) Total Score","description":"The change between the SDS total score at each assessed visit and the total score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment.","timeFrame":"Baseline and Weeks 12, 24, 36, and 52"},{"measure":"Change From Baseline in SDS Work/School Subscale","description":"The change between the Sheehan Disability work/school subscale score at each assessed visit and work/school subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.","timeFrame":"Baseline and Weeks 12, 24, 36, and 52"},{"measure":"Change From Baseline in SDS Social Life Subscale","description":"The change between the Sheehan Disability social life subscale score at each assessed visit and social life subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.","timeFrame":"Baseline and Weeks 12, 24, 36, and 52"},{"measure":"Change From Baseline in SDS Family Life/Home Responsibilities Subscale","description":"The change between the Sheehan Disability family life/home responsibilities subscale score at each assessed visit and family life/home responsibilities subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.","timeFrame":"Baseline and Weeks 12, 24, 36, and 52"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has completed either study LuAA21004\\_315 ( NCT01153009), LuAA21004\\_316 (NCT01163266), or LuAA21004\\_317 (NCT01179516) immediately prior to enrollment in the extension study (ie, the baseline visit is the same visit as the Week 8 \\[Lu AA21004\\_317\\] or Week 10 \\[Lu AA21004\\_315 or Lu AA21004\\_316\\] assessment of the preceding protocol).\n* Suffers from a recurrent major depressive episode) as the primary diagnosis according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria (classification code 296.3x) at entry into the prior study.\n* Twelve-month continuation treatment with Lu AA21004 is indicated for the treatment of this participant according to the opinion of the investigator.\n* Females of childbearing potential who are sexually active with a nonsterilized male partner agree to routinely use adequate contraception throughout the duration of the study.\n\nExclusion Criteria:\n\n* Has Major Depressive Disorder for whom other psychiatric disorders (mania, bipolar disorder, schizophrenia, or any psychotic disorder) have been diagnosed during the prior study.\n* In the investigator's clinical judgment, has a significant risk of suicide and/or a score of ≥5 points on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression Rating Scale (MADRS).\n* In the opinion of the investigator, is unlikely to comply with the clinical study protocol or is unsuitable for any reason.\n* Has a clinically significant moderate or severe ongoing adverse event related to study medication from the prior study.\n* Has used/uses disallowed concomitant medication.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"77 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Senior Medical Director","affiliation":"Takeda","role":"STUDY_DIRECTOR"}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Patients who completed Studies LuAA21004\\_315 (NCT01153009), LuAA21004\\_316 (NCT01163266), and LuAA21004\\_317 (NCT01179516) and were willing to continue, and judged by the investigator to benefit from a 52-week continuation treatment with Lu AA21004, were enrolled and received flexible doses of study drug, based on patient response and tolerability.","recruitmentDetails":"Participants took part in the study at 143 investigative sites in the United States from 07 Sep 2010 to 31 May 2013.","groups":[{"id":"FG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"1075"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"1073"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"538"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"537"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"142"}]},{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"115"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"112"}]},{"type":"Lack of Efficacy","reasons":[{"groupId":"FG000","numSubjects":"68"}]},{"type":"Noncompliance","reasons":[{"groupId":"FG000","numSubjects":"41"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"36"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"22"}]},{"type":"Elevated liver enzymes","reasons":[{"groupId":"FG000","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"1075"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44.5","spread":"12.05"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"790"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"285"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Caucasian (or White, including Hispanic)","categories":[{"measurements":[{"groupId":"BG000","value":"813"}]}]},{"title":"Black/African American","categories":[{"measurements":[{"groupId":"BG000","value":"249"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"7"}]}]},{"title":"American Indian/Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"5"}]}]},{"title":"Native Hawaiian/Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"1"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"Hispanic or Latino","categories":[{"measurements":[{"groupId":"BG000","value":"104"}]}]},{"title":"Non-Hispanic and Non-Latino","categories":[{"measurements":[{"groupId":"BG000","value":"971"}]}]}]},{"title":"Weight","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg)","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"88.77","spread":"24.160"}]}]}]},{"title":"Body Mass Index (BMI)","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"31.60","spread":"8.061"}]}]}]},{"title":"Height","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"cm","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"167.44","spread":"9.456"}]}]}]},{"title":"Montgomery Åsberg Depression Rating Scale (MADRS) total score","description":"MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"20.0","spread":"10.70"}]}]}]},{"title":"Hamilton Anxiety Scale (HAM-A) total score","description":"HAM-A is a 14 item rating scale to quantify anxiety symptomatology severity (i.e., anxious mood, tension, fear, insomnia, etc.) rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56. Higher scores indicate greater severity of symptoms.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"11.6","spread":"6.65"}]}]}]},{"title":"Clinical Global Impression - Severity scale (CGI-S) score","description":"The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: \"Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?\" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill). Higher scores indicate greater severity of illness.","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"scores on a scale","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"3.3","spread":"1.21"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5%","description":"Treatment-emergent adverse events (TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.","populationDescription":"Safety set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Over the 52 week period","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1073"}]}],"classes":[{"title":"Nausea","categories":[{"measurements":[{"groupId":"OG000","value":"258"}]}]},{"title":"Diarrhea","categories":[{"measurements":[{"groupId":"OG000","value":"80"}]}]},{"title":"Vomiting","categories":[{"measurements":[{"groupId":"OG000","value":"68"}]}]},{"title":"Constipation","categories":[{"measurements":[{"groupId":"OG000","value":"65"}]}]},{"title":"Nasopharyngitis","categories":[{"measurements":[{"groupId":"OG000","value":"68"}]}]},{"title":"Viral upper respiratory tract infection","categories":[{"measurements":[{"groupId":"OG000","value":"66"}]}]},{"title":"Upper respiratory tract infection","categories":[{"measurements":[{"groupId":"OG000","value":"60"}]}]},{"title":"Weight increased","categories":[{"measurements":[{"groupId":"OG000","value":"65"}]}]},{"title":"Headache","categories":[{"measurements":[{"groupId":"OG000","value":"136"}]}]},{"title":"Insomnia","categories":[{"measurements":[{"groupId":"OG000","value":"56"}]}]}]},{"type":"PRIMARY","title":"Number of Participants With Serious Treatment-Emergent Adverse Events","description":"Serious treatment-emergent adverse events (serious-TEAE) are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A serious-TEAE may also be a pretreatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing. Serious Adverse Events include adverse events that result in death, require either inpatient hospitalization or the prolongation of hospitalization, are life-threatening, result in a persistent or significant disability/incapacity or result in a congenital anomaly/birth defect. Other important medical events, based upon appropriate medical judgment, may also be considered serious adverse events if a trial participant's health is at risk and intervention is required to prevent an outcome mentioned.","populationDescription":"Safety set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Over the 52 week period","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1073"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}]}]},{"type":"PRIMARY","title":"Treatment-Emergent Adverse Events Leading to Study Discontinuation","description":"Treatment-emergent adverse events are adverse events with an onset that occurs after receiving study drug and within 30 days after receiving the last dose of study drug. A TEAE may also be a pre-treatment adverse event or a concurrent medical condition diagnosed prior to the date of first dose of study drug that increases in severity after the start of dosing.","populationDescription":"Safety set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Over the 52 week period","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1073"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"117"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score","description":"The change between MADRS total score at each assessed visit and MADRS score at baseline. MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (i.e., apparent sadness, reported sadness, inner tension, etc.) rated on a 7-point Likert scale from 0 (normal) to 6 (most abnormal) with a total score range from 0 to 60. Higher scores indicate greater severity of symptoms.","populationDescription":"Safety set, observed cases (OC)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Weeks 1, 2, 4, 8, 12, 16, 20, 24, 28, 36, 44, and 52","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1043"}]}],"classes":[{"title":"Week 1 (n=1043)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.7","spread":"6.32"}]}]},{"title":"Week 2 (n=1043)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"7.50"}]}]},{"title":"Week 4 (n=1004)","categories":[{"measurements":[{"groupId":"OG000","value":"-6.1","spread":"8.50"}]}]},{"title":"Week 8 (n=936)","categories":[{"measurements":[{"groupId":"OG000","value":"-7.9","spread":"9.19"}]}]},{"title":"Week 12 (n=843)","categories":[{"measurements":[{"groupId":"OG000","value":"-8.5","spread":"9.55"}]}]},{"title":"Week 16 (n=777)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.1","spread":"9.50"}]}]},{"title":"Week 20 (n=747)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.4","spread":"10.03"}]}]},{"title":"Week 24 (n=697)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"9.64"}]}]},{"title":"Week 28 (n=670)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.5","spread":"10.20"}]}]},{"title":"Week 36 (n=617)","categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"10.44"}]}]},{"title":"Week 44 (n=573)","categories":[{"measurements":[{"groupId":"OG000","value":"-10.3","spread":"10.70"}]}]},{"title":"Week 52 (n=534)","categories":[{"measurements":[{"groupId":"OG000","value":"-10.3","spread":"11.00"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score","description":"The change between HAM-A score at each assessed visit and HAM-A score at baseline. HAM-A is a 14 item rating scale to quantify anxiety symptomatology severity (i.e., anxious mood, tension, fear, insomnia, etc.) rated on a 5-point scale from 0 (not present) to 4 (severe) with a total score range from 0 to 56. Higher scores indicate greater severity of symptoms.","populationDescription":"Safety set, observed cases (OC)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Weeks 4, 24, and 52","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1029"}]}],"classes":[{"title":"Week 4 (n=1029)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.6","spread":"4.98"}]}]},{"title":"Week 24 (n=742)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.2","spread":"5.84"}]}]},{"title":"Week 52 (n=548)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.8","spread":"6.52"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression Scale-Severity of Illness (CGI-S)","description":"The change between CGI-S score at each assessed visit and CGI-S score at baseline. The CGI-S assesses the clinician's impression of the subject's current state of mental illness and consists of one question for the investigator: \"Considering your total clinical experience with this particular population, how mentally ill is the patient at this time?\" which is rated on a seven-point scale (1=normal, not ill at all; 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=extremely ill). Higher scores indicate greater severity of illness.","populationDescription":"Safety set, observed cases (OC)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Weeks 4, 24, and 52","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"1030"}]}],"classes":[{"title":"Week 4 (n=1030)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.6","spread":"0.99"}]}]},{"title":"Week 24 (n=743)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"1.16"}]}]},{"title":"Week 52 (n=549)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"1.32"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Sheehan Disability Scale (SDS) Total Score","description":"The change between the SDS total score at each assessed visit and the total score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely) with a total score range from 0 to 30. Higher scores indicate greater severity of impairment.","populationDescription":"Safety set, observed cases (OC)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Weeks 12, 24, 36, and 52","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"650"}]}],"classes":[{"title":"Week 12 (n=650)","categories":[{"measurements":[{"groupId":"OG000","value":"-2.8","spread":"6.69"}]}]},{"title":"Week 24 (n=494)","categories":[{"measurements":[{"groupId":"OG000","value":"-3.9","spread":"6.88"}]}]},{"title":"Week 36 (n=414)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.0","spread":"7.37"}]}]},{"title":"Week 52 (n=381)","categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"7.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SDS Work/School Subscale","description":"The change between the Sheehan Disability work/school subscale score at each assessed visit and work/school subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.","populationDescription":"Safety set, observed cases (OC)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Weeks 12, 24, 36, and 52","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"650"}]}],"classes":[{"title":"Week 12 (n=650)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"2.42"}]}]},{"title":"Week 24 (n=494)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"2.48"}]}]},{"title":"Week 36 (n=414)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.2","spread":"2.60"}]}]},{"title":"Week 52 (n=381)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"2.61"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SDS Social Life Subscale","description":"The change between the Sheehan Disability social life subscale score at each assessed visit and social life subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.","populationDescription":"Safety set, observed cases (OC)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Weeks 12, 24, 36, and 52","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"}]}],"classes":[{"title":"Week 12 (n=942)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.0","spread":"2.53"}]}]},{"title":"Week 24 (n=721)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"2.55"}]}]},{"title":"Week 36 (n=617)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"2.82"}]}]},{"title":"Week 52 (n=545)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"2.85"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in SDS Family Life/Home Responsibilities Subscale","description":"The change between the Sheehan Disability family life/home responsibilities subscale score at each assessed visit and family life/home responsibilities subscale score collected at baseline. The SDS is a 3 item rating scale to assess functional impairment (panic, anxiety, phobic and depressive symptoms) over three inter-related domains (work/school, social life, and family life/home responsibilities) rated on an 11 point scale from 0 (not at all) to 10 (extremely). Higher scores indicate greater severity of impairment.","populationDescription":"Safety set, observed cases (OC)","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline and Weeks 12, 24, 36, and 52","groups":[{"id":"OG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"942"}]}],"classes":[{"title":"Week 12 (n=942)","categories":[{"measurements":[{"groupId":"OG000","value":"-0.9","spread":"2.39"}]}]},{"title":"Week 24 (n=721)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"2.47"}]}]},{"title":"Week 36 (n=617)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"2.74"}]}]},{"title":"Week 52 (n=545)","categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"2.76"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"56 weeks","description":"At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.","eventGroups":[{"id":"EG000","title":"Vortioxetine","description":"Vortioxetine 10 mg, capsules, orally, once daily for the first week of treatment; then vortioxetine up-titrated to 15 mg or 20 mg, capsules, orally, once daily for up to 51 weeks.","seriousNumAffected":29,"seriousNumAtRisk":1073,"otherNumAffected":854,"otherNumAtRisk":1073}],"seriousEvents":[{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Esophageal rupture","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1073}]},{"term":"Cholecystitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Latent syphilis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Periorbital cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Wound sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Ankle fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Intentional overdose","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Wrist fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Breast cancer female","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":1073}]},{"term":"Bone cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Breast cancer stage I","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Malignant melanoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Uterine leiomyoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Complicated migraine","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Transient ischemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Abortion spontaneous","organSystem":"Pregnancy, puerperium and perinatal conditions","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Suicide attempt","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":1073}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Suicidal ideation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Asthma","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]},{"term":"Phlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":1073}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":258,"numAtRisk":1073}]},{"term":"Diarrhea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":80,"numAtRisk":1073}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":68,"numAtRisk":1073}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":65,"numAtRisk":1073}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":68,"numAtRisk":1073}]},{"term":"Viral upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":66,"numAtRisk":1073}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":60,"numAtRisk":1073}]},{"term":"Weight increased","organSystem":"Investigations","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":65,"numAtRisk":1073}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":136,"numAtRisk":1073}]},{"term":"Insomnia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA (16.0)","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":56,"numAtRisk":1073}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property."},"pointOfContact":{"title":"Medical Director, Clinical Science","organization":"Takeda","email":"clinicaltrialregistry@tpna.com","phone":"800-778-2860"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-10-13"},"conditionBrowseModule":{"meshes":[{"id":"D003865","term":"Depressive Disorder, Major"},{"id":"D003863","term":"Depression"},{"id":"D003866","term":"Depressive Disorder"}],"ancestors":[{"id":"D019964","term":"Mood Disorders"},{"id":"D001523","term":"Mental Disorders"},{"id":"D001526","term":"Behavioral Symptoms"},{"id":"D001519","term":"Behavior"}]},"interventionBrowseModule":{"meshes":[{"id":"D000078784","term":"Vortioxetine"}],"ancestors":[{"id":"D010879","term":"Piperazines"},{"id":"D006573","term":"Heterocyclic Compounds, 1-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"}]}},"hasResults":true}